Bortezomib will improve the level or effect of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. Increased flibanserin adverse outcomes may come about if coadministered with many weak CYP3A4 inhibitors. Remedy triggers peripheral neuropathy (predominantly sensory); nonetheless, instances of extreme sensory and motor peripheral neuropathy have a... https://patrickq998fsd2.wikicommunications.com/user